10-QPeriod: Q2 FY1996

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 1996

Filed August 14, 1996For Securities:BIIB

Summary

This filing represents Biogen Inc.'s (BIIB) 10-Q Quarterly Report as of August 14, 1996. As this is a historical filing from the mid-1990s, it reflects a very different stage in the company's development. The report would detail the company's financial performance and position during that specific quarter. Investors should note that information pertaining to product pipelines, revenue sources, and competitive landscapes from this era will be significantly outdated compared to current company operations and market conditions. Given the age of the report, its primary value lies in historical research or understanding Biogen's long-term evolution. It is not suitable for making current investment decisions without substantial additional, up-to-date information. Investors looking at this period should consider the nascent biotechnology industry of the time and Biogen's specific therapeutic areas and research programs as they were then, which may have evolved or been discontinued.

Key Highlights

  • 1This is a 10-Q filing for Biogen Inc. (BIIB) dated August 14, 1996.
  • 2The filing pertains to the quarterly financial performance and position of Biogen Inc.
  • 3This report reflects the company's operations and financial status from the mid-1990s.
  • 4The context is the early biotechnology industry, with likely different product pipelines and revenue streams compared to today.
  • 5This historical filing is primarily of interest for understanding Biogen's long-term development and historical financial trends.
  • 6Investors should exercise caution, as this information is not current and not suitable for making present-day investment decisions.

Frequently Asked Questions

This 10-Q filing provides a quarterly update on Biogen Inc.'s financial performance, operational results, and financial position as of August 14, 1996. It's a standard SEC disclosure for public companies.

No, this filing is from 1996 and is highly outdated. The biotechnology industry and Biogen itself have undergone significant changes since then. Current product portfolios, research pipelines, market conditions, and financial performance will be vastly different. This report is useful for historical analysis only.

In 1996, Biogen was a pioneer in biotechnology, likely focusing on areas such as recombinant DNA technology, interferons, and potentially early research into areas that would eventually lead to treatments for diseases like multiple sclerosis and hepatitis. Specific product details would be outlined in the full report.

The provided text is a directory listing of the SEC filing's location. To access the actual financial data and detailed management discussion, you would need to navigate to the linked '.txt' or related HTML files within the SEC's EDGAR database for the filing number 0000936392-96-000630.